Condition
Polyneuropathy, Inflammatory Demyelinating, Chronic
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Completed1
Recruiting1
Active Not Recruiting1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06290128Phase 3Active Not Recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06968975RecruitingPrimary
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
NCT06859099Phase 3Enrolling By InvitationPrimary
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT01847937Completed
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
Showing all 4 trials